CST3 and chronic kidney disease: While cystatin C has demonstrated predictive value for cardiovascular and non-cardiovascular mortality in specific populations such as patients with diabetes [17], stroke [18,19], CKD patients [20] and the older population [14,21], its predictive capacity for long-term mortality outcomes in the general population has not been extensively investigated.